|

Risankizumab Clinical Trials

5 actively recruiting trials across 5 locations

▲ +1 trial since June 2026

Also known as: ABBV-066, Skyrizi

Pipeline

Phase 2: 2Phase 3: 2

Top Sponsors

  • AbbVie3
  • NYU Langone Health1
  • MoonLake Immunotherapeutics AG1

Indications

  • Arthritis5
  • Rheumatic Disease1
  • Juvenile Psoriatic Arthritis1
  • Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment1
  • Psoriatic Arthritis1

Avondale, Arizona1 trial

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Clinical Site

Phase 3

Little Rock, Arkansas1 trial

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Arkansas Children's Hospital /ID# 258776

Phase 3

Huntington Beach, California1 trial

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Newport Huntington Medical Group /ID# 272764

Phase 2

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Morrisville, North Carolina1 trial

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

Evidera, a PPD Business Unit /ID# 238688

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.